Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aikaterini Foska

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Journal of Clinical Medicine|December 30, 2025
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Maria Chondrogianni, et al.
Neurological Research and Practice|June 14, 2021
Optic disc drusen mimicking Idiopathic Intracranial Hypertension (IIH): rely on ultrasoundEleni Bakola, Dimitrios Alonistiotis, Chryssa Arvaniti, et al.
Stroke|January 5, 2023
Cortical Superficial Siderosis and Transient Focal Neurological Episode Preceding Lobar Hemorrhage in Cerebral Amyloid AngiopathyAikaterini Theodorou, Maria Chondrogianni, Eleni Bakola, et al.
Toxins|November 26, 2025
OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Maria Chondrogianni, et al.
Frontiers in Neurology|February 4, 2026
Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study groupMichail Vikelis, Andreas A Argyriou, Maria Chondrogianni, et al.
The Neurohospitalist|December 19, 2022
Telltale Signs of Idiopathic Intracranial Hypertension With Normal Opening Cerebrospinal Fluid PressureAikaterini Foska, Lina Palaiodimou, Maria Ioanna Stefanou, et al.
The Neurologist|January 4, 2021
True Restriction in Diffusion-Weighted Imaging in a Mistreated Patient With PhenylketonuriaLina Palaiodimou, Christina Zompola, Stefanos Lachanis, et al.
Cephalalgia : an International Journal of Headache|June 4, 2026
Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study groupAndreas A Argyriou, Emmanouil V Dermitzakis, Dimitrios Rikos, et al.
European Journal of Neurology|August 14, 2025
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Neurological Research and Practice|February 8, 2022
Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardyMaria Ioanna Stefanou, Eleni Karachaliou, Maria Chondrogianni, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Journal of Clinical Medicine|December 30, 2025
Testing the Efficacy of Eptinezumab 100 mg in the Early Prevention of Chronic Migraine over Weeks 1 to 4: Prospective Real-World Data from the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Maria Chondrogianni, et al.
Neurological Research and Practice|June 14, 2021
Optic disc drusen mimicking Idiopathic Intracranial Hypertension (IIH): rely on ultrasoundEleni Bakola, Dimitrios Alonistiotis, Chryssa Arvaniti, et al.
Stroke|January 5, 2023
Cortical Superficial Siderosis and Transient Focal Neurological Episode Preceding Lobar Hemorrhage in Cerebral Amyloid AngiopathyAikaterini Theodorou, Maria Chondrogianni, Eleni Bakola, et al.
Toxins|November 26, 2025
OnabotulinumtoxinA to Prevent Chronic Migraine with Comorbid Bruxism: Real-World Data from the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Maria Chondrogianni, et al.
Frontiers in Neurology|February 4, 2026
Efficacy of single-dose galcanezumab 240 mg on episodic or refractory chronic cluster headache: prospective, 4-week, real-world evidence from the GRASP study groupMichail Vikelis, Andreas A Argyriou, Maria Chondrogianni, et al.
The Neurohospitalist|December 19, 2022
Telltale Signs of Idiopathic Intracranial Hypertension With Normal Opening Cerebrospinal Fluid PressureAikaterini Foska, Lina Palaiodimou, Maria Ioanna Stefanou, et al.
The Neurologist|January 4, 2021
True Restriction in Diffusion-Weighted Imaging in a Mistreated Patient With PhenylketonuriaLina Palaiodimou, Christina Zompola, Stefanos Lachanis, et al.
Cephalalgia : an International Journal of Headache|June 4, 2026
Achieving International Headache Society-aspired optimal migraine control in fremanezumab-treated patients: A post-hoc analysis of a real-world, prospective study from the GRASP study groupAndreas A Argyriou, Emmanouil V Dermitzakis, Dimitrios Rikos, et al.
European Journal of Neurology|August 14, 2025
Effects of Pausing and Re-Initiating Fremanezumab After Continuous 24-Month Treatment for Preventing Difficult-To-Treat Migraine: Prospective, Multicenter, Real-World Data From the GRASP Study GroupAndreas A Argyriou, Emmanouil V Dermitzakis, Georgia Xiromerisiou, et al.
Neurological Research and Practice|February 8, 2022
Guillain-Barré syndrome and fulminant encephalomyelitis following Ad26.COV2.S vaccination: double jeopardyMaria Ioanna Stefanou, Eleni Karachaliou, Maria Chondrogianni, et al.
Pageof 2